캐나다 - 영어 - Health Canada

auro pharma inc - flecainide acetate - tablet - 50mg - flecainide acetate 50mg - class ic antiarrythmics

캐나다 - 영어 - Health Canada

auro pharma inc - flecainide acetate - tablet - 100mg - flecainide acetate 100mg - class ic antiarrythmics

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - flecainide acetate 100mg;   - tablet - 100 mg - active: flecainide acetate 100mg   excipient: croscarmellose sodium magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified water - in patients without structural heart disease and without myocardial infarction, flecainide bnm tablets are indicated for the prevention of: supraventricular arrhythmias · paroxysmal supraventricular tachycardias (psvt) including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms; · paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. ventricular arrhythmias · documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia (vt) if they are considered life-threatening in the judgement of the attending physician. not indicated for less severe ventricular arrhythmias even if symptomatic. use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - flecainide acetate 50mg;   - tablet - 50 mg - active: flecainide acetate 50mg   excipient: croscarmellose sodium magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch - in patients without structural heart disease and without myocardial infarction, flecainide bnm tablets are indicated for the prevention of: supraventricular arrhythmias · paroxysmal supraventricular tachycardias (psvt) including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms; · paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. ventricular arrhythmias · documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia (vt) if they are considered life-threatening in the judgement of the attending physician. not indicated for less severe ventricular arrhythmias even if symptomatic. use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.

미국 - 영어 - NLM (National Library of Medicine)

avera mckennan hospital - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg

미국 - 영어 - NLM (National Library of Medicine)

kaiser foundation hospitals - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 100 mg

미국 - 영어 - NLM (National Library of Medicine)

apotex corp. - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 50 mg

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

teva b.v. - flecainide acetate - tablet - 100 milligram(s) - antiarrhythmics, class ic; flecainide

미국 - 영어 - NLM (National Library of Medicine)

avera mckennan hospital - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 100 mg

미국 - 영어 - NLM (National Library of Medicine)

american health packaging - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - flecainide acetate 100 mg